Chronic Heart Failure (CHF) Drugs market is segmented by Type and by Application. Players, stakeholders, and other participants in the global Chronic Heart Failure (CHF) Drugs market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on sales, revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Anti-clotting (Aspirin)
Antiplatelet Medicines (Clopidogrel, Prasugrel, and Ticagrelor)
Anticoagulant Medicines (Warfarin)
Blood Pressure Maintaining Agents (Angiotensin Converting Enzyme (ACE) Inhibitors)
Angiotensin II Receptor Blockers (ARB)
Statins
Diuretics
Nitrates
Segment by Application
Hospital
Clinic
Others
By Company
Abbott
Johnson & Johnson
Merck
Stanley Pharmaceuticals
New Haven Pharmaceuticals, Inc.
Pfizer
GlaxoSmithKline plc
Novartis International AG
Biovail Corporation
Bristol-Myers Squibb Company
Symplmed Pharmaceuticals
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
